SmartCella Holding AB
Sabine Ott serves as the Chief Commercial Officer at SmartCella Holding AB since March 2025. Prior to this role, Sabine held several pivotal positions, including Senior Vice President of Business Development and Licensing at Revvity from May 2023 to March 2025, following the acquisition of Sirion by Revvity. In a concurrent role at Horizon Discovery, also part of Revvity, from October 2021 to March 2025, Sabine focused on business development and licensing for PinPoint Base Editing technologies. Previously, Sabine had a long tenure at SIRION BIOTECH GmbH, leading business development and licensing efforts for gene and cell therapy from April 2016 to March 2025. Earlier roles include Head of Business Development at GeneWake GmbH, Managing Director of the Research Association ForZebRA, and various positions at MWG Biotech AG. Sabine's academic background includes a Master's and Doctorate in Biology/Genetics from the University of Konstanz, along with a Bachelor's in Biology from Ludwig-Maximilian University Munich.
This person is not in any teams
This person is not in any offices
SmartCella Holding AB
SmartCella, founded in 2014, is an innovative biotechnology company based in Stockholm, Sweden. SmartCella’s vision is to combine first-in-class delivery platforms with cutting-edge cell and gene therapies to unleash the full potential of targeted therapies. The company has three main business units, Smartwise, SmartCella Solutions and Procella. Smartwise is developing and manufacturing a first-in-class endovascular delivery device, the Extroducer, that enables direct tissue/organ infusions through the vessel wall directly into to hard-to-reach organs and tumors. There is a significant unmet need in the field of targeted delivery of different types of therapies for regeneration of tissue and for treatment of cancer tumors. Smartwise received regulatory approval from the US FDA for the Extroducer in June 2022 and is now actively out-licensing the technology to global companies with therapies that benefit from direct delivery. SmartCella Solutions create novel mRNA therapies and platforms that enable cell-mediated delivery of protein and mRNA to specific regions, even within organs or microenvironments. A pipeline of projects within regeneration and tolerization, focusing on oncology, is in pre-clinical development. Procella has advanced capabilities within stem cell therapy development and inhouse cGMP manufacturing of cell based therapies, with a proven platform to take stem cell projects from discovery phase to clinical development. A globally licensed cardiac stem cell therapy is entering clinical stages (in collaboration with AstraZeneca) and there is a growing pipeline of projects in different stages of development, with dopamine producing cells for Parkinson´s Disease and our own iMSCs most advanced.